首页> 外文期刊>BMC Gastroenterology >Artificial neural network-based models used for predicting 28- and 90-day mortality of patients with hepatitis B-associated acute-on-chronic liver failure
【24h】

Artificial neural network-based models used for predicting 28- and 90-day mortality of patients with hepatitis B-associated acute-on-chronic liver failure

机译:基于人工神经网络的模型用于预测乙型肝炎患者患者的28和90天死亡率

获取原文
           

摘要

This study aimed to develop prognostic models for predicting 28- and 90-day mortality rates of hepatitis B virus (HBV)-associated acute-on-chronic liver failure (HBV-ACLF) through artificial neural network (ANN) systems. Six hundred and eight-four cases of consecutive HBV-ACLF patients were retrospectively reviewed. Four hundred and twenty-three cases were used for training and constructing ANN models, and the remaining 261 cases were for validating the established models. Predictors associated with mortality were determined by univariate analysis and were then included in ANN models for predicting prognosis of mortality. The receiver operating characteristic curve analysis was used to evaluate the predictive performance of the ANN models in comparison with various current prognostic models. Variables with statistically significant difference or important clinical characteristics were input in the ANN training process, and eight independent risk factors, including age, hepatic encephalopathy, serum sodium, prothrombin activity, γ-glutamyltransferase, hepatitis B e antigen, alkaline phosphatase and total bilirubin, were eventually used to establish ANN models. For 28-day mortality in the training cohort, the model’s predictive accuracy (AUR 0.948, 95% CI 0.925–0.970) was significantly higher than that of the Model for End-stage Liver Disease (MELD), MELD-sodium (MELD-Na), Chronic Liver Failure-ACLF (CLIF-ACLF), and Child-Turcotte-Pugh (CTP) (all p 0.05). For 90-day mortality in the training cohort, the model’s predictive accuracy (AUR 0.913, 95% CI 0.887–0.938) was significantly higher than that of MELD, MELD-Na, CTP and CLIF-ACLF (all p 0.05). The established ANN models can more accurately predict short-term mortality risk in patients with HBV- ACLF. The main content has been postered as an abstract at the AASLD Hepatology Conference (https://doi.org/10.1002/hep.30257).
机译:该研究旨在通过人工神经网络(ANN)系统,开发预测预测乙型肝炎病毒(HBV)急性对慢性肝功能衰竭(HBV-ACLF)的28- + 90天死亡率的预后模型。回顾性审查了六百六十四例连续HBV-ACLF患者。四百二十三种案例用于培训和构建ANN模型,其余261例案例用于验证已建立的模型。与死亡率相关的预测因子由单变量分析确定,然后包括在ANN模型中,以预测死亡率的预后。接收器操作特性曲线分析用于评估与各种电流预后模型相比的ANN模型的预测性能。具有统计学上显着或重要临床特征的变量在ANN训练过程中输入,以及八个独立的危险因素,包括年龄,肝脑病,血清钠,凝血酶体活性,γ-谷氨酰胺转移酶,乙型肝炎E抗原,碱性磷酸酶和总胆红素,最终用于建立ANN模型。培训队列的28天死亡率,该模型的预测精度(AUR 0.948,95%CI 0.925-0.970)显着高于终末期肝病(MELD),融合钠(MELD-NA)的模型),慢性肝功能衰竭-ACLF(CLIF-ACLF),以及儿童TURCOTTE-PUGH(CTP)(所有P 0.05)。培训队列中90天死亡率,该模型的预测精度(AUR 0.913,95%CI 0.887-0.938)显着高于MELD,MELD-NA,CTP和CLIF-ACLF(所有P 0.05)。已建立的ANN模型可以更准确地预测HBV-ACLF患者的短期死亡率风险。主要内容在AASLD Hepatology会议上被引入摘要(HTTPS://Doi.org/10.1002 / Hep.30257)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号